Therapeutic Constructs

Using proprietary drug discovery technologies,
CytomX Therapeutics has devised a novel approach to developing protease-activated antibody therapeutics, termed Probodies™. Probodies™ combine the well-established power and specificity of monoclonal antibodies with a second level of tissue selectivity, driven by the action of endogenous disease enzymes. Compared to standard antibodies, we believe that Probodies™ will have reduced mechanism-based toxicities and potentially higher therapeutic indices.

Probodies™ to two oncology targets are currently undergoing preclinical evaluation. 

Protein Engineering Platforms

CytomX has developed powerful bacterial display tools that enable the discovery and optimization of peptides with improved properties when compared to existing discovery approaches. DisplayX (patented) and CLiPS (Cellular Libraries of Peptide Substrates – patent pending), have enabled the discovery of novel molecules with properties superior to those obtained using other commercially available technologies. By combining these platform technologies, we are generating new molecules that more specifically target the sites of disease.

______________________________________________________________________________________________

References

Thomas JM, Daugherty PS, Proligands with protease-regulated binding activity identified from cell-displayed prodomain libraries.  Protein Sci. 2009 Oct; 18(10):2053-9.

Daugherty PS, Protein engineering with bacterial display. Curr Opin Struct Biol. 2007 Aug; 17(4):474-80.

Bessette, PH, Hu, X, Soh, HT, Daugherty, PS, Microfluidic Library Screening for Mapping Antibody Epitopes. Anal Chem. 2007 Mar 1;79(5):2174-8. Epub 2007 Jan 26.

Boulware KT, Daugherty PS. Protease specificity determination by using cellular libraries of peptide substrates (CLiPS). Proc Natl Acad Sci U S A. 2006 May 16; 103(20): 7583-8.

Rice JJ, Schohn A, Bessette PH, Boulware KT, Daugherty PS. Bacterial display using circularly permuted outer membrane protein OmpX yields high affinity peptide ligands. Protein Sci. 2006 Apr; 15 (4): 825-36.